Effects of direct thrombin or factor Xa inhibition on clot thrombogenicity in vitro: comparison of dabigatran with rivaroxaban and apixaban

被引：0
|
作者：
van Ryn, J. [1 ]
Kink-Eiband, M. [1 ]
Kuritsch, I [1 ]
Wienen, W. [2 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Drug Discovery Support, Biberach, Germany
[2] Boehringer Ingelheim GmbH & Co KG, Pulm Res, Biberach, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-181
引用
收藏
页码：687 / 688
页数：2
相关论文
共 50 条
  • [1] Effects of direct thrombin or factor Xa inhibition on clot thrombogenicity in vitro: Comparison of dabigatran with rivaroxaban and apixaban
    Van Ryn, J.
    Kink-Eiband, M.
    Kuritsch, I.
    Wienen, W.
    EUROPEAN HEART JOURNAL, 2009, 30 : 332 - 333
  • [2] Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits
    Wong, P. C.
    Crain, E. J.
    Watson, C. A.
    Xin, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (08) : 1313 - 1320
  • [3] An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban
    Wan, Huaibin
    Yang, Yanmin
    Zhu, Jun
    Wu, Shuang
    Zhou, Zhou
    Huang, Bi
    Wang, Juan
    Shao, Xinghui
    Zhang, Han
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (08) : 882 - 885
  • [4] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Graff, Jochen
    Harder, Sebastian
    CLINICAL PHARMACOKINETICS, 2013, 52 (04) : 243 - 254
  • [5] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Jochen Graff
    Sebastian Harder
    Clinical Pharmacokinetics, 2013, 52 : 243 - 254
  • [6] Comparative Antithrombotic and Antihemostatic Effects of the Direct Factor Xa Inhibitors, Apixaban and Rivaroxaban, and the Direct Thrombin Inhibitors, Dabigatran and Lepirudin, in Rabbit Models of Venous Thrombosis and Bleeding Time
    Wong, Pancras C.
    Crain, Earl, Jr.
    Watson, Carol
    BLOOD, 2008, 112 (11) : 1040 - 1041
  • [7] The effects of direct thrombin or factor Xa inhibition with dabigatran or rivaroxaban on plaque formation and endothelial function in apolipoprotein E-deficient mice
    Lee, I. -O.
    Kratz, M. T.
    Schirmer, S. H.
    Baumhaekel, M.
    Boehm, M.
    EUROPEAN HEART JOURNAL, 2012, 33 : 199 - 199
  • [8] Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma.
    van Ryn, Joanne
    Kink-Eiband, Monika
    Hauel, Norbert
    Priepke, Henning
    Wienen, Wolfgang
    BLOOD, 2007, 110 (11) : 558A - 558A
  • [9] Oral factor Xa anticoagulants, rivaroxaban and apixaban, enhance clot dissolution in plasma
    Carter, R. L.
    Talbot, K.
    Smith, T.
    Lee, A. Y.
    Pryzdial, E. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 673 - 673
  • [10] Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
    Jiang, Xiaosui
    Crain, Earl J.
    Luettgen, Joseph M.
    Schumacher, William A.
    Wong, Pancras C.
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (04) : 780 - 782
12345